Abstract
Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have